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Background: Optimizing outcomes in Respiratory Syncytial Virus (RSV) pneumonia requires 
accurate diagnosis and determination of severity that, in resource-limited settings, is often based 
on clinical assessment alone. We describe host inflammatory biomarkers and clinical outcomes 
among children hospitalized with RSV lower respiratory tract infection (LRTI) in Uganda and 
controls with rhinovirus and pneumococcal pneumonia. 
Methods: 58 children hospitalized with LRTI were included. We compared 37 patients with 
RSV, 10 control patients with rhinovirus, and 11 control patients with suspected pneumococcal 
pneumonia.   
Results: Patients in the RSV group had significantly lower levels of C-Reactive Protein (CRP) 
and Chitinase-3-Like Protein 1 (CHI3L1) than the pneumococcal pneumonia group (p<0.05 for 
both). Among children with RSV, higher admission levels of CRP predicted prolonged time to 
resolution of tachypnea, tachycardia, and fever. Higher levels of CHI3L1 were associated with 
higher composite clinical severity scores and predicted prolonged time to resolution of tachypnea 
and tachycardia, time to wean oxygen, and time to sit. Higher levels of Lipocalin-2 (LCN2) 
predicted prolonged time to resolution of tachypnea, tachycardia and time to feed. Higher 
admission levels of all three biomarkers were predictive of a higher total volume of oxygen 
administered during hospitalization (p<0.05 for all comparisons). Of note, CHI3L1 and LCN2 
appeared to predict clinical outcomes more accurately than CRP, the inflammatory biomarker 
most widely used in clinical practice.  
Conclusions: Our findings suggest that CHI3L1 and LCN2 may be clinically informative 
biomarkers in childhood RSV LRTI in low-resource settings. 
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Introduction 
 
Respiratory Syncytial Virus is a leading cause of lower respiratory tract infection (LRTI) 
globally. In 2015, RSV resulted in approximately 3.2 million childhood hospital admissions and 
118,200 deaths, 99% of which occurred in low- and middle-income countries (2). RSV is an 
enveloped RNA paramyxovirus that is highly infectious via droplet transmission. The severity of 
RSV respiratory infections can be attributed largely to the host immune response, which is 
characterized by neutrophil-mediated inflammation of the airways (1). 
 
There is significant overlap between the clinical manifestations of RSV LRTI and bacterial 
pneumonia, which may lead to the inappropriate use of antimicrobials in patients with RSV. The 
current WHO and UNICEF integrated management of childhood illness (IMCI) guidelines for 
the management of childhood LRTI in low-resource settings include cough, difficulty breathing, 
tachypnea and chest in-drawing as clinical criteria for the administration of empiric dispersible 
amoxicillin (3). These criteria are sensitive and will capture most children with bacterial 
pneumonia; however, a large number of patients meeting these clinical criteria will have RSV 
infection and will not benefit from antibiotic therapy. Effective management of pediatric LRTI in 
low resource settings also requires determination of severity and prognosis to guide resource 
allocation, prioritize the sickest patients, and prevent fatality (4). Although clinical 
characteristics and outcomes of children with RSV infection have been well documented in 
resource-intensive settings (5), fewer data are available from low-resource settings where access 
to viral diagnostics is limited.  
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Biomarkers of host response to infection may have clinical utility in distinguishing between 
infectious etiology and determining disease severity in LRTI (6). Proteomic signatures from 
blood samples have been shown to provide rapid and actionable clinical information capable of 
guiding treatment decisions (7). Several candidate biomarkers of systemic inflammation have 
been examined in LRTI, including C-Reactive Protein (CRP) (6), Chitinase-3-Like Protein 1 
(CHI3L1) (8) and Lipocalin-2 (LCN2) (9). While some studies have examined these biomarkers 
in pediatric LRTI in low resource settings (10, 11), none have examined their potential clinical 
utility in RSV patients or as predictors of clinical course and outcome. 
 
The objective of this study was to describe admission characteristics, radiographic and laboratory 
abnormalities, inflammatory biomarker levels at admission, clinical course, and outcomes of 
children hospitalized with RSV LRTI in Uganda. We compared cases with RSV LRTI to two 
control groups: (1) rhinovirus respiratory tract infection (RTI); and (2) suspected pneumococcal 
(Streptococcus pneumoniae, Sp) lobar pneumonia. 
 
Materials and Methods 
 
Study design and participants 
We conducted a prospective study of children hospitalized with signs of pneumonia at two 
resource-limited hospitals in Uganda: Jinja Regional Referral Hospital and Kambuga District 
Hospital. Children were included if they: (1) were under 13 years of age; (2) required admission 
to hospital; and (3) presented with cough or difficulty breathing and one or more of the following 
signs: tachypnea, chest in-drawing, and/or hypoxemia. Of note, all children included in this study 
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met the WHO and UNICEF IMCI clinical definition of pneumonia (3). Children with clinically-
suspected tuberculosis were excluded.  
 
Enrolled children underwent history and physical exam, had blood and nasopharyngeal (NP) 
swabs collected, and were followed over the course of admission until discharge, death, or 
transfer to another facility with frequent monitoring of vital signs. Cases of RSV LRTI were 
defined as patients meeting the above clinical inclusion criteria, plus detection of RSV from the 
nasopharynx by multiplex PCR. Two control groups were chosen: (1) rhinovirus RTI, defined as 
patients meeting the clinical inclusion criteria, plus rhinovirus detected in the nasopharynx and 
absence of lobar consolidation on CXR; and (2) Sp pneumonia, defined as patients meeting the 
clinical inclusion criteria, plus lobar consolidation on CXR and Sp detected in the blood or at 
high genomic load (>6.9 log10 copies/mL) in the nasopharynx. Of note, high density colonization 
with Sp in the nasopharynx in children with clinical pneumonia, above a threshold of 6.9 log10 
copies/mL, has previously been associated with invasive pneumococcal infection (12).  
 
Specimen collection and analysis 
Staff were trained in correct procedures for flocked nasopharyngeal (NP) swab collection 
(FLOQSwabs™, Copan Diagnostics, Murrieta, CA, USA). NP swabs were placed into viral 
transport medium (UTM™, Universal Transport Medium, Copan Diagnostics, Murrieta, CA, 
USA) and 1mL aliquots of viral transport medium were stored at -80°C prior to shipment to 
Canada. A semi-automated nucleic acid extraction protocol was used to perform nucleic acid 
extraction with a KingFisher™ mL Purification System (Thermo Fisher Scientific Inc, Waltham, 
MA) and the MagaZorb® Total RNA Mini-Prep Kit (Promega, Madison, WI). Quantitative real-
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time PCR (qPCR) with FTDResp33 (Fast-Track Diagnostics, Esch-sur-Alzet, Luxembourg) was 
used to identify respiratory pathogens in the NP swab. We ran these samples using an Applied 
Biosystems® 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA). To quantify 
the number of genome copies of Sp present in each sample, we used the standard curves relating 
the rtPCR cycle threshold (CT) to plasmid DNA concentrations provided by the manufacturer. 
EDTA plasma was collected in the field and stored at -80°C until shipment to Canada. ELISAs 
were performed according to the manufacturer’s instructions and blinded to all associated 
clinical data in order to quantify the following biomarkers: CRP, CHI3L1, LCN2 (R&D 
Systems, Minneapolis, MN). Dilutions for CRP ranged from 1:500,000 to 1:5000 to achieve an 
assay range of 500 to 0.16 µg/ml. Dilutions for CHI3L1 ranged from 1:62.5 to 1:1800 in order to 
achieve a range of 3600 to 2 nm/ml. Dilutions for LCN2 ranged from 1:20 to 1:200 to achieve a 
range of 500 to 1.6 ng/ml. Background signal was determined from blank wells on each plate and 
subtracted from all samples and standards prior to analysis. A 4-parameter logistic regression 
curve fitted to data was used to determine biomarker concentrations from the ELISA optical 
density. 
 
Statistical analysis 
Continuous data was presented as medians (interquartile range) and analyzed non-parametrically, 
with relationships assessed using the Mann-Whitney U test. Categorical data were analyzed 
using Pearson’s χ2 test. Time-to-event analysis was performed using Kaplan-Meier plots and log-
rank test for differences between factor levels. Cases were right censored at the time of last 
encounter. Where multiple p-values were calculated, we used the Bonferroni correction for 
multiple statistical comparisons, to avoid family-wise inflation of type 1 statistical error.  
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Ethics statement 
The study was approved by the School of Biomedical Sciences Research and Ethics Committee 
(Makerere University, Kampala, Uganda), the Uganda National Council of Science and 
Technology, and the Human Research Ethics Board of the University of Alberta. Accompanying 
legal guardians provided informed written consent for participants at the time of enrolment.  
 
Results 
Fifty-eight children hospitalized with RTIs between February 25, 2014 and July 3, 2015 were 
included: 37 patients with RSV LRTI, 11 with rhinovirus RTI, and 10 with Sp pneumonia. Table 
1 shows clinical characteristics of the study cohort. Patients in the control groups were 
significantly older and weighed more than the children in the RSV case group. Co-detection of 
multiple pathogens was common, such that 1 out of 37 patients with RSV LRTI also met 
inclusion criteria for the rhinovirus control group, and 4 out of 37 also met inclusion criteria for 
the Sp pneumonia control group. We accounted for this overlap in microbial classification in a 
subsequent sensitivity analysis. 
Clinical course and outcomes  
Recovery times for clinically relevant endpoints are shown in Table 2. Of note, time to resolution 
of fever and tachypnea and time to feed were significantly prolonged in patients with Sp 
pneumonia compared to those with RSV LRTI. 
Host inflammatory biomarkers distinguish RSV from suspected pneumococcal pneumonia 
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Table 3 and Figure 1 show plasma concentrations of several host biomarkers. Among patients 
with RSV LRTI, inflammatory biomarkers were correlated with each other (CHI3L1 with LCN2 
ρ = +0.82, p<0.001; CHI3L1 with CRP ρ = +0.62, p <0.001; LCN2 with CRP, ρ= +0.75, p 
<0.001). Markers of systemic inflammation (CRP, CHI3L1 and LCN2) were significantly higher 
in the Sp pneumonia group than the RSV LRTI and rhinovirus RTI groups. Differences in CRP, 
CHI3L1, but not LCN2, remained statistically significant following correction for multiple 
comparisons. In linear regression models adjusting for the potentially confounding effect of age, 
Sp pneumonia remained independently associated with higher CRP (p=0.002) and CHI3L1 
(p=0.034), relative to RSV LRTI. Some patients had multiple organisms detected simultaneously 
in the NP, such that one patient in the RSV LRTI group also fulfilled criteria for rhinovirus RTI 
and four patients in the RSV LRTI group also fulfilled criteria for Sp pneumonia. We performed 
a sensitivity analysis, excluding those patients with overlapping microbial classifications, and 
found that differences in CRP and CHI3L1 between patients with RSV LRTI and Sp pneumonia 
remained statistically significant (p<0.01 for both comparisons).  
 
Predictive value of inflammatory biomarkers among children with RSV LRTI 
Higher levels of CHI3L1 were associated with higher composite clinical severity scores (RISC), 
r= 0.41, p =0.019). Admission biomarker levels directly correlated with recovery times within 
the RSV LRTI group (n=37): higher admission levels of CHI3L1 were associated with prolonged 
time to resolution of tachypnea and tachycardia, time to wean oxygen, and time to sit (p<0.05 for 
all comparisons). Similarly, higher admission levels of LCN2 at admission were associated with 
prolonged time to resolution of tachypnea, tachycardia and time to feed. In contrast, higher 
admission CRP levels were not significantly associated with any of these endpoints. Higher 
11 
 
admission levels of CHI3L1, LCN2 and CRP, however, were all predictive of a higher total 
volume of oxygen administered over the course of hospitalization (p<0.05 for all comparisons). 
Prognostic biomarkers are illustrated in Figure 2, with the cohort dichotomized according to 
median admission biomarker values (CHI3L1, 32 ng/mL; LCN2, 94 ng/mL; and CRP, 18 
µg/mL). The biomarkers outperformed clinical variables, including tachypnea and RISC score, 
as predictors of recovery times. For full results see Table, Supplementary Digital Content.  
 
Discussion 
In sub-Saharan Africa, RSV is commonly detected in children with severe acute respiratory 
illness (13) and is a significant predictor of hospitalization (14). This study provided a unique 
examination of clinical features and host inflammatory biomarkers in Ugandan children 
hospitalized with RSV LRTI. Noteworthy strengths of this study include the use of a sensitive 
molecular virology assay and host biomarker measurement in patients from a low-resource 
setting where such laboratory data are not usually available, as well as detailed longitudinal 
follow-up of hospitalized children. Our main findings included: (1) RSV-infected children had 
significantly lower CRP and CHI3L1 levels compared to a Sp pneumonia control group; and (2) 
admission levels of CHI3L1 and LCN2 were predictive of clinical outcomes in children with 
RSV LRTI.  
 
The clinical characteristics of our cohort were broadly consistent with prior studies of children 
with RSV LRTI; however, children in our study had evidence of greater disease severity, 
including higher respiratory rates, lower oxygen saturation, and a higher proportion with chest 
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in-drawing (15-17). Control children with Sp pneumonia were more frequently lethargic and 
tachycardic. 
 
CRP is an acute phase protein produced in response to inflammatory cytokines and is widely 
used as a biomarker of systemic inflammation in clinical practice (18). We found that CRP was 
lower in patients with RSV LRTI compared to those with suspected Sp pneumonia, consistent 
with previous reports that demonstrated the diagnostic utility of CRP as a marker of serious 
bacterial infection (6).  
 
We found that admission levels of CHI3L1 were lower in children with RSV LRTI than Sp 
pneumonia, but similar between RSV LRTI and rhinovirus RTI. Furthermore, among children 
with RSV LRTI, higher levels of CHI3L1 and LCN2 predicted longer recovery times. CHI3L1 is 
a secreted glycoprotein expressed by immune and respiratory epithelial cells that promotes 
bacterial clearance and augments host tolerance to infection in pneumococcal pneumonia (8). In 
past studies, CHI3L1 was elevated in RSV respiratory infection (20) and higher CHI3L1was 
associated with radiographic consolidation in African children with clinical signs of pneumonia 
(11). LCN2 is a secreted transport protein produced by neutrophils in the respiratory mucosa that 
inhibits bacterial uptake of iron and propagates inflammation via IL-8 mediated induction of 
neutrophils (21). In past studies, LCN2 distinguished between pneumonia etiology (9), was 
associated with pneumonia severity (9), and predicted poor outcomes in childhood 
pneumococcal pneumonia (10). Our findings build on these observations, suggesting that 
CHI3L1 and LCN2 are clinically informative biomarkers in childhood RSV LRTI in a low-
resource setting. They may have utility as diagnostic markers to distinguish viral (RSV and 
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rhinovirus) RTI from Sp pneumonia and/or prognostic markers of prolonged recovery time in 
children with RSV LRTI.  
 
Several factors limit the validity and generalizability of these data. The statistical power of this study 
was restricted by a small sample size. Diagnostic workup was incomplete, since we did not have 
access to blood culture or lung aspirates at our low-resource hospital. Further studies would be 
needed to determine the clinical utility of these biomarkers used in real-time for pneumonia triage 
and management. Co-detection of multiple pathogens complicated the comparison between RSV 
LRTI cases and controls; however, we performed sensitivity analyses and demonstrated that our 
conclusions were robust to exclusion of patients with multiple co-detected micro-organisms.  
 
Findings from the current study may have several implications. Protein biomarkers that could be 
adapted to a rapid test platform might be used to discriminate bacterial from viral etiology in order to 
help guide responsible antibiotic usage. Analogous to the HRP2 rapid diagnostic test for malaria, 
such a test could be inexpensive and achieve rapid penetration to clinical settings in low-resource 
settings. In Sub-Saharan Africa, the combination of a high burden of communicable diseases and 
lack of diagnostic capacity is leading to increased rates of antimicrobial resistance (22), which 
may be combatted by limiting the use of antimicrobials for patients with viral illness (23). 
Secondly, prognostic biomarkers such as CHI3L1 and LCN2 may help to guide resource 
allocation and supportive management decisions. This finding is relevant for resource-scarce 
healthcare settings where triage to high-dependency units should prioritize cases of the greatest 
severity in order to prevent fatality. Finally, our study shows that high levels of CHI3L1 and 
LCN2 are associated with either bacterial infection or more severe viral infection, but are not 
elevated in mild viral infection. In clinical practice, low levels of these biomarkers could be used 
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to rule out serious infection and identify children with mild viral illness who could be managed 
as outpatients without antibiotics. Further studies to examine the utility of CHI3L1 and LCN2 in 
guiding clinical decision-making are warranted. 
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Figure Legends 
Figure 1: Levels of host inflammatory biomarkers in 58 African children hospitalized with 
respiratory tract infection. CRP (A), CHI3L1 (B), and LCN2 (C) were similar in the RSV 
LRTI group (closed diamonds) compared to the rhinovirus RTI control group (open circles), but 
significantly lower than the Sp pneumonia control group (closed circles). Co-detection of 
rhinovirus or Sp in the RSV group is indicated by marker shape. 
 
Figure 2: Time to resolution of tachypnea and total oxygen volume consumed in 37 African 
children hospitalized with RSV LRTI, dichotomized by median admission biomarker 
levels. CRP levels at admission did not correlate significantly with time to resolution of 
tachypnea or total oxygen volume consumed (A); Children with admission CHI3L1 >32ng/mL 
(B) and LCN2 >94ng/mL (C) remained tachypneic longer and consumed more oxygen than 
children with lower levels of CHI3L1 or LCN2.  
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Table: Times to clinical endpoint in days measured in 58 African children hospitalized with 
respiratory tract infection, dichotomized by median biomarker values. Clinical markers 
(tachypnea and RISC) are given as comparators 
CRP 
 ≤18ug/mL >18ug/mL P-value 
Time to resolution of tachypnea 0.85 (0-2.2)1 1.5 (0.28-2.6)1 0.11 
Time to resolution of tachycardia 0.30 (0-0.67) 0.54 (0.17-0.90) 0.47 
Time to resolution of fever 0.1 (0-0.22) 0.26 (0-0.52) 0.33 
Time to wean oxygen 3.0 (1.9-4.0) 4.3 (1.8-6.9) 0.39 
Time to breastfeed or eat 0.09 (0-0.18) 0.03 (0-0.07) 0.13 
Time to sit 0.32 (0-0.83) 0.41 (0.043-0.77) 0.896 
CHI3L1 
 ≤32ug/mL >32ug/mL P-value 
Time to resolution of tachypnea 0.70 (0-2.1)1 1.5 (0-4.5)1 0.017* 
Time to resolution of tachycardia 0.017 (0-0.18) 1.0 (0-3.0) <0.001* 
Time to resolution of fever 0.12 (0.03-0.22) 0.27 (0-0.62) 0.486 
Time to wean oxygen 2.2 (0.79-3.7)1 4.7 (3.4-6.0)1 0.009* 
Time to breastfeed or eat 0.02 (0-0.07) 0.02 (0-0.17) 0.297 
Time to sit 0.036 (0-0.25) 0.62 (0-2.0) 0.018* 
LCN2 
 ≤95ng/mL >94ng/mL  
Time to resolution of tachypnea 0.68 (0.45-1.6)1 2.1 (2.3-4.5)1 0.016* 
Time to resolution of tachycardia 0.039 (0-0.93) 0.84 (0.34-1.3) 0.001* 
Time to resolution of fever 0.097 (0-0.2) 0.28 (0-0.58) 0.16 
Time to wean oxygen 2.9 (1.6-4.2) 4.5 (2.3-6.7) 0.378 
Time to breastfeed or eat 02 0.098 (0-0.50) 0.025* 
Time to sit 0.11 (0-0.51) 0.57 (0-2.0) 0.10 
Respiratory Rate for Age3 
 No Tachypnea Tachypnea P-value 
Time to resolution of tachypnea 0 2.87 (0.0-19.88) 0.147 
Time to resolution of tachycardia 0.31 (0.00-1.9) 1.03 (0.00-19.74) 0.468 
Time to resolution of fever 0.68 (0.0-0.54) 0.69 (0.0-19.74) 0.147 
Time to wean oxygen 2.8 (0.0-7.54) 3.29 (0.0-16.88) 1.0 
Time to breastfeed or eat 0.079 (0.0-0.71) 0.12 (0.0-0.92) 0.493 
Time to sit 02 0.33 (0.0-2.03) 0.344 
RISC Score 
 ≤3 >3 P-value 
Time to resolution of tachypnea 2.46 (0.0-19.88) 2.75 (0.0-10.09) 0.777 
Time to resolution of tachycardia 0.97 (0-19.74) 0.82 (0-4.8) 0.777 
Time to resolution of fever 0.78 (0-19.74) 0.18 (0-1.28) 0.777 
Time to wean oxygen 3.24 (0-16.88) 3.16 (0-12.72) 0.777 
Time to breastfeed or eat 0.058 (0-0.71) 0.23 (0-0.92) 0.065 
Time to sit 0.25 (0-2.03) 0.41 (0-1.34) 0.844 
* Indicates a statistically significant difference (p<0.05) between groups. 
Times to endpoint are in days and expressed as mean (range), unless otherwise indicated 
1Indicates time to endpoint expressed in median (IQR) 
2All patients feeding from time of admission 
3Respiratory rate>99th percentile for age{Fleming, 2011 #1}. 
